Skip to main content
Premium Trial:

Request an Annual Quote

Znomics Signs Sponsored Research Agreement with U of Utah for Drug Discovery in Zebrafish

NEW YORK (GenomeWeb News) – Zebrafish screening firm Znomics said yesterday that it is collaborating with the University of Utah’s Huntsman Cancer Institute to develop pre-clinical compounds to treat T-cell leukemia, autoimmune diseases, inflammation, and complications related to organ transplantation.
 
Znomics said in a statement that it will fund the program and “receive full commercial rights to the discoveries.”
 
Under the terms of the agreement, Nikolaus Trede, assistant professor in the department of pediatrics at the University of Utah School of Medicine, will work with Znomics researchers to develop proprietary T-cell disease assays in the zebrafish.
 
The partners will then use these assays to screen the university's library of compounds to identify leads that will be further developed for clinical testing.
 
Trede is also joining Znomics' scientific advisory board as part of the agreement.
 
Znomics President and Chief Scientific Officer Roger Cone said in a statement that the zebrafish is a promising platform to identify compounds useful for treating diseases involving T cells “because we can model the biology of the T cell in the whole animal environment."
 
Znomics CEO Richard Sessions said that the firm plans to have “preclinical compounds for three major diseases by 2010," and that the agreement with the University of Utah “puts us in good position to achieve the goal, possibly even earlier."
 
Financial terms of the collaboration were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.